Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane

Bone

Volumn 40, Issue 4, 2007, Pages 876-887

  Miki, Yasuhiro ^a   Suzuki, Takashi ^a   Hatori, Masahito ^a   Igarashi, Katsuhide ^b   Aisaki, Ken ich ^b   Kanno, Jun ^b   Nakamura, Yasuhiro ^a   Uzuki, Miwa ^c   Sawai, Takashi ^b   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Androgen; Aromatase inhibitor; Estrogen; Exemestane; Osteoblast

Indexed keywords

ALKALINE PHOSPHATASE; AMINOGLUTETHIMIDE; ANDROGEN; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; BONE MORPHOGENETIC PROTEIN; CYTOSKELETON PROTEIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FLUTAMIDE; MESSENGER RNA; TESTOSTERONE;

ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OSTEOBLAST; POSTMENOPAUSE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

ALKALINE PHOSPHATASE; AMINOGLUTETHIMIDE; ANDROSTADIENES; AROMATASE INHIBITORS; BASE SEQUENCE; CELL LINE; CELL PROLIFERATION; DNA PRIMERS; ESTRADIOL; FLUTAMIDE; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; RECEPTORS, ANDROGEN; RNA, MESSENGER; TESTOSTERONE; TESTOSTERONE CONGENERS;

EID: 33847765402     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.11.029     Document Type: Article

References (50)

1. Rogers J. Estrogens in the menopause and postmenopause. N. Engl. J. Med. 280 (1969) 364-367
2. Wingate L. The epidemiology of osteoporosis. J. Med. 15 (1984) 245-266
3. Felson D.T., Zhang Y., Hannan M.T., Kiel D.P., Wilson P.W., and Anderson J.J. The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329 (1993) 1141-1146
4. Lester L., and Coleman R. Bone loss and the aromatase inhibitors. Br. J. Cancer 93 (2005) S16-S22
5. Miller W.R., and Dixon J.M. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin. Breast Cancer 1 (2000) S9-S14
6. Lønning P.E., Paridaens R., Thurlimann B., Piscitelli G., and di Salle E. Exemestane experience in breast cancer treatment. J. Steroid Biochem. Mol. Biol. 61 (1997) 151-155
7. Center for Drug Evaluation and Research Application Number NDA 20753 (Exemestane) Medical Review. Food and Drug Administration, 1999.
8. Goss P.E., Qi S., Josse R.G., Pritzker K.P.H., Mendes M., Hu H., et al. The steroidal Aromatase inhibitor exemestane prevent bone loss in ovariectomized rats. Bone 34 (2004) 384-392
9. Goss P.E., Qi S., Cheung A.M., Hu H., Mendes M., and Pritzker K.P.H. Effects of steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in the ovariectomized rats. Clin. Cancer Res. 10 (2004) 5717-5723
10. Sasano H., Uzuki M., Sawai T., Nagura H., Matsunaga G., Kashimoto O., et al. Aromatase in human bone tissue. J. Bone Miner. Res. 12 (1997) 1416-1423
11. Schweikert H.U., Wolf L., and Romalo G. Oestrogen formation from Androstendione in human bone. Clin. Endocrinol. 43 (1995) 37-42
12. Purohit A., Flanagan A.M., and Reed M.J. Estrogen synthesis by osteoblast cell lines. Endocrinology 131 (1992) 2027-2029
13. Tanaka S., Haji M., Nishi Y., Yanase T., Takayanagi R., and Nawata H. Aromatase activity in human osteoblast-like osteosarcoma cell. Calcif. Tissue Int. 52 (1993) 107-109
14. Recanatini M., Bisi A., Cavalli A., Belluti F., Gobbi S., Rampa A., et al. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J. Med. Chem. 44 (2001) 672-680
15. Linkhart T.A., Mohan S., and Baylink D.J. Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 19 (1996) 1S-12S
16. Harris S.A., Enger R.J., Riggs B.L., and Spelsberg T.C. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J. Bone Miner. Res. 10 (1995) 178-186
17. Suzuki T., Darnel A.D., Akahira J.I., Ariga N., Ogawa S., Kaneko C., et al. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J. Clin. Endocrinol. Metab. 86 (2001) 2250-2257
18. Miki Y., Suzuki T., Tazawa C., Ishizuka M., Semba S., Gorai I., et al. Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Müllerian duct cells using microarray. Cancer Lett. 220 (2005) 197-210
19. Yamamoto M., Takahashi Y., and Tabata Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 24 (2003) 4375-4383
20. Kanno J., Aisaki K., Igarashi K., Nakatsu N., Ono A., Kodama Y., et al. "Per cell" normalization method for mRNA measurement by quantitative PCR and microarrays. BMC Genomics 29 (2006) 64
21. Eisen M.B., Spellman P.T., Brown P.O., and Bostein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14863-14868
22. Miki Y., Nakata T., Suzuki T., Darnel A.D., Moriya T., Kaneko C., et al. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J. Clin. Endcrinol. Metab. 87 (2002) 5760-5768
23. Ishizuka M., Hatori M., Suzuki T., Miki Y., Darnel A.D., Tazawa C., et al. Sex steroid receptors in rheumatoid arthritis. Clin. Sci. (Lond.) 106 (2004) 293-300
24. Rodan G.A., and Noda M. Gene expression in osteoblastic cells. Crit. Rev. Eukaryot. Gene Expr. 1 (1991) 85-98
25. Ito Y., and Miyazono K. RUNX transcription factors as key role of TGF-β superfamily signaling. Curr. Opin. Genet. Dev. 13 (2003) 43-47
26. Lønning P.E., Geisler J., Krag L.E., Erikstein B., Bremnes Y., Hagen A.I., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically respected early breast cancer. J. Clin. Oncol. 23 (2005) 4847-4849
27. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
28. Coleman R.E., Banks L.M., Girgis S.I., Vrdoljak E., Fox J., Porter L.S., et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES)-2 years bone mineral density (BMD) and bone biomarker data. Breast Cancer Res. Treat. 94 (2005) S233
29. Vottero A., Stratalis C.A., Ghizzoni L., Longui C.A., Karl M., and Chrousos G.P. Androgen receptor-mediated hypersensitivity to androgen in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. J. Clin. Endocrinol. Metab. 84 (1999) 1091-1095
30. Brum I.S., Spritzer P.M., Paris F., Maturana M.A., Audran F., and Sultan C. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women. J. Soc. Gynecol. Investig. 12 (2005) 135-141
31. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., and Ohlsson C. Androgens and bone. Endocr. Rev. 25 (2004) 389-425
32. Turner A., Chen T., Barber T., Malabanan A., Holick M., and Tangpricha V. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin. Endocrinol. (Oxf.) 61 (2004) 560-566
33. Ruetsche A.G., Kneubuehl R., Birkhaeuser M.H., and Lippuner K. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporos. Int. 16 (2005) 791-798
34. Kasperk C.H., Wergedal J.E., Farley J.R., Linkhart T.A., Turner R.T., and Baylink D.J. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 124 (1989) 1576-1578
35. Kasperk C., Fitzsimmons R., Strong D., Mohan S., Jennings J., Wergedal J., et al. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J. Clin. Endocrinol. Metab. 71 (1990) 1322-1329
36. Chen Q., Kaji H., Kanatani M., Sugimoto T., and Chihara K. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm. Metab. Res. 36 (2004) 674-678
37. Bord S., Horner A., Beavan S., and Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86 (2001) 2309-2314
38. Sala A., and Watson R. B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments. J. Cell. Physiol. 179 (1999) 245-250
39. Chalhoub N., Benachenhou N., Rajapurohitam V., Pata M., Ferron M., Frattini A., et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat. Med. 9 (2003) 399-406
40. Boulet A.M., and Capecchi M.R. Multiple roles of Hoxa11 and Hoxd11 in the formation of the mammalian forelimb zeugopod. Development 131 (2004) 299-309
41. Lundberg P., Lundgren I., Mukohyama H., Lehenkari P.P., Horton M.A., and Lerner U.H. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. Endocrinology 142 (2001) 339-347
42. Gutierrez J., Osses N., and Brandan E. Changes in secreted and cell associated proteoglycan synthesis during conversion of myoblasts to osteoblasts in response to bone morphogenetic protein-2: role of decorin in cell response to BMP-2. J. Cell. Physiol. 206 (2006) 58-67
43. Omi M., Fisher M., Maihle N.J., and Dealy C.N. Studies on epidermal growth factor receptor signaling in vertebrate limb patterning. Dev. Dyn. 233 (2005) 288-300
44. Rodan G.A., Raisz L.G., and Bilezikian J.P. Pathophysiology of osteoporosis. (chapter 73). In: Bilezikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of bone biology. 2nd ed. vol. 1 (2002), Academic Press, A division of Harcourt, Inc., NY, USA 1275-1290
45. Kellinsalmi M., Monkkonen H., Monkkonen J., Leskela H.V., Parikka V., Hamalainen M., et al. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin. Pharmacol. Toxicol. 97 (2005) 382-391
46. Chen Q., Kaji H., Sugimoto T., and Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 491 (2001) 91-93
47. Abu E.O., Horner A., Kusec V., Triffitt J.T., and Compston J.E. The localization of androgen receptors in human bone. J. Clin. Endocrinol. Metab. 82 (1997) 3493-3497
48. Wiren K.M., and Orwoll E.S. Androgens: receptor expression and steroid action in bone. (chapter 43). In: Bilezikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of bone biology. 2nd ed. vol. 1 (2002), Academic Press, A division of Harcourt, Inc., NY, USA 757-772
49. Chow L.W., Wong J.L., and Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J. Steroid Biochem. Mol. Biol. 86 (2003) 443-447
50. Sato T., Morita I., Sakaguchi K., Nakahama K.I., Smith W.L., Dewitt D.L., et al. Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast-like cell formation induced by interleukin-1 beta. J. Bone Miner. Res. 11 (1996) 392-400